pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,573 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Half of states sue over Medicaid work requirements
    FDA peptide panelists, a new study on Covid and flu shots, and more health news from Morning Rounds
    STAT · 26d ago↗ source
  • Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe disease
    Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking…
    Endpoints · 26d ago↗ source
  • Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
    Bristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team. Bain Capital, the Canada Pension Plan Investment Board, and Bristol…
← prev
page 20 of 63
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 26d ago
↗ source
  • BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
    BeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. T…
    Endpoints · 26d ago↗ source
  • House China panel probes Bristol Myers, Pfizer on use of trial sites
    A congressional committee has opened an inquiry into Bristol Myers Squibb and Pfizer's use of clinical trial sites in China, including facilities that the committee's chairman said are affiliated w…
    Endpoints · 26d ago↗ source
  • STAT+: Even with MAHA, Trump administration has gone soft on alcohol
    A STAT investigation has found that the Trump administration has downplayed alcohol’s risks and actively derailed efforts to understand and prevent drinking-related harms. 
    STAT · 26d ago↗ source
  • Opinion: Florida is the first state to require EKGs for high school athletes. It’s a mistake
    “There are better ways for schools to protect student athletes,” writes Katherine Hofmann.
    STAT · 26d ago↗ source
  • STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
    The Trump administration's grand bargain with drugmakers isn't working out as planned.
    STAT · 26d ago↗ source
  • Opinion: Short-sighted new student loan caps elevate chiropractic care over critical health care professions
    “This administrative logic is hopelessly out of touch with the empirical reality of American health care,” writes David S. Shapiro.
    STAT · 26d ago↗ source
  • STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
    Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
    STAT · 26d ago↗ source
  • STAT+: FDA’s top gene therapy regulator is leaving his role
    The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
    STAT · 26d ago↗ source
  • NEJM retracts pivotal data for Amgen's Tavneos
    Pivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the re…
    Endpoints · 26d ago↗ source
  • STAT+: AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney general
    AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions paid for by Texas Medicaid.
    STAT · 26d ago↗ source
  • STAT+: 26 states sue to block Medicaid work requirements
    States argue the rules will make it too hard for people to get the Medicaid coverage they're entitled too.
    STAT · 26d ago↗ source
  • John Reed on J&J’s R&D model, oncology deals and pipeline expansion potential
    John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving him unique insight into h…
    Endpoints · 26d ago↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 26d ago↗ source
  • EU lobby urges member states to improve Europe’s life sciences sector
    More than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter was addressed to EU member stat…
    Endpoints · 26d ago↗ source
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 26d ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 26d ago↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 26d ago↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…
    Endpoints · 26d ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…
    Endpoints · 26d ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…
    Endpoints · 27d ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 27d ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 27d ago↗ source